Non-insulin therapies for diabetes
Pro Research Analysisby 
Searched over 200M research papers
Non-Insulin Therapies for Diabetes: Overview and Key Drug Classes
Non-insulin therapies play a significant role in diabetes management, especially for type 2 diabetes, but are also being explored as adjuncts in type 1 diabetes. These therapies aim to improve blood sugar control, reduce insulin requirements, and address side effects like weight gain and hypoglycemia Garg2013Wright2019Frandsen2018+3 MORE.
Common Non-Insulin Drug Classes for Diabetes
The most widely used non-insulin drugs include metformin, sulfonylureas, and thiazolidinediones. These medications are especially common in type 2 diabetes, with metformin being the most frequently prescribed . Other important classes are:
- Glucagon-like peptide-1 (GLP-1) receptor agonists
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Sodium-glucose co-transporter (SGLT1 and SGLT2) inhibitors
- Amylin analogs (e.g., pramlintide) Wright2019Frandsen2018Angueira2013+1 MORE
Non-Insulin Therapies in Type 1 Diabetes
While insulin remains the main treatment for type 1 diabetes, non-insulin drugs are being studied as add-ons to help patients who struggle to reach glycemic targets or who experience side effects from insulin alone Wright2019Frandsen2018Frandsen2016+1 MORE.
Efficacy and Benefits
- Non-insulin therapies as adjuncts to insulin can lead to modest improvements in HbA1c (average reduction of 0.2–0.5%) and weight loss Wright2019Frandsen2018Angueira2013+2 MORE.
- These drugs can also reduce daily insulin requirements and help with weight control Wright2019Frandsen2018Frandsen2016+1 MORE.
- Some agents, like GLP-1 receptor agonists and SGLT inhibitors, show promise for additional benefits such as cardiovascular and renal protection, especially in patients at high risk .
Risks and Limitations
- The use of non-insulin therapies in type 1 diabetes can increase the risk of hypoglycemia and gastrointestinal side effects Wright2019Frandsen2018Frandsen2016+1 MORE.
- Some drugs, particularly SGLT inhibitors, may increase the risk of acidosis-related events .
- The overall effect on glycemic control is generally modest, and more research is needed to identify which patients benefit most Frandsen2018Frandsen2016.
Non-Insulin Therapies in Type 2 Diabetes
Non-insulin drugs are the preferred first-line treatment for type 2 diabetes, especially in the early stages. They are effective in lowering blood glucose, often with fewer side effects compared to insulin Garg2013Angueira2013Ayalon-Dangur2023+3 MORE.
Inpatient and Outpatient Use
- In hospitalized patients with type 2 diabetes, non-insulin therapies (alone or combined with insulin) can safely control blood sugar and reduce hypoglycemia risk Ayalon-Dangur2023Galindo2022Pasquel2021.
- Newer guidelines and studies support the use of oral agents like DPP-4 inhibitors and GLP-1 agonists in selected hospitalized patients, moving away from a strict insulin-only approach Galindo2022Pasquel2021.
Combination Therapy
- Combining non-insulin drugs with insulin can lead to better blood sugar control, lower insulin doses, and less weight gain compared to insulin alone .
- This approach is increasingly favored for many patients with type 2 diabetes, both in and out of the hospital Ayalon-Dangur2023Galindo2022Cahn2015+1 MORE.
Conclusion
Non-insulin therapies are essential in the management of type 2 diabetes and are being explored as adjuncts in type 1 diabetes. They offer benefits such as improved glycemic control, weight management, and reduced insulin requirements, but may carry risks like hypoglycemia and gastrointestinal side effects. Ongoing research aims to better define which patients benefit most from these therapies and how to optimize their use alongside insulin for both type 1 and type 2 diabetes Garg2013Wright2019Frandsen2018+7 MORE.
Sources and full results
Most relevant research papers on this topic